These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23178231)

  • 1. Putative neuroprotective agents in neuropsychiatric disorders.
    Dodd S; Maes M; Anderson G; Dean OM; Moylan S; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():135-45. PubMed ID: 23178231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness.
    Robertson OD; Coronado NG; Sethi R; Berk M; Dodd S
    Early Interv Psychiatry; 2019 Oct; 13(5):1032-1049. PubMed ID: 30690898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.
    Moylan S; Maes M; Wray NR; Berk M
    Mol Psychiatry; 2013 May; 18(5):595-606. PubMed ID: 22525486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial dysfunction and psychiatric disorders.
    Rezin GT; Amboni G; Zugno AI; Quevedo J; Streck EL
    Neurochem Res; 2009 Jun; 34(6):1021-9. PubMed ID: 18979198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lithium: principles and rules of use].
    Pinabel F; Hardy P
    Rev Prat; 1999 Nov; 49(18):2053-9. PubMed ID: 10626495
    [No Abstract]   [Full Text] [Related]  

  • 6. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.
    Berk M; Kapczinski F; Andreazza AC; Dean OM; Giorlando F; Maes M; Yücel M; Gama CS; Dodd S; Dean B; Magalhães PV; Amminger P; McGorry P; Malhi GS
    Neurosci Biobehav Rev; 2011 Jan; 35(3):804-17. PubMed ID: 20934453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenines: from the perspective of major psychiatric disorders.
    Myint AM
    FEBS J; 2012 Apr; 279(8):1375-85. PubMed ID: 22404766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases.
    Quinones MP; Kaddurah-Daouk R
    Neurobiol Dis; 2009 Aug; 35(2):165-76. PubMed ID: 19303440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders.
    Bauer M; Alda M; Priller J; Young LT;
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S250-4. PubMed ID: 14677087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability?
    Steen NE; Methlie P; Lorentzen S; Hope S; Barrett EA; Larsson S; Mork E; Almås B; Løvås K; Agartz I; Melle I; Berg JP; Andreassen OA
    J Clin Psychiatry; 2011 Nov; 72(11):1515-21. PubMed ID: 21367348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional differences in human ependymal and subventricular zone cytoarchitecture are unchanged in neuropsychiatric disease.
    Comte I; Kotagiri P; Szele FG
    Dev Neurosci; 2012; 34(4):299-309. PubMed ID: 22831917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise of N-acetylcysteine in neuropsychiatry.
    Berk M; Malhi GS; Gray LJ; Dean OM
    Trends Pharmacol Sci; 2013 Mar; 34(3):167-77. PubMed ID: 23369637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness.
    Manji HK; Moore GJ; Chen G
    J Clin Psychiatry; 2000; 61 Suppl 9():82-96. PubMed ID: 10826666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From neuroprogression to neuroprotection: implications for clinical care.
    Berk M; Conus P; Kapczinski F; Andreazza AC; Yücel M; Wood SJ; Pantelis C; Malhi GS; Dodd S; Bechdolf A; Amminger GP; Hickie IB; McGorry PD
    Med J Aust; 2010 Aug; 193(S4):S36-40. PubMed ID: 20712560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stress system in the human brain in depression and neurodegeneration.
    Swaab DF; Bao AM; Lucassen PJ
    Ageing Res Rev; 2005 May; 4(2):141-94. PubMed ID: 15996533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of Oxidative Stress and Neuroprogression in Depression Disorder.
    Vaváková M; Ďuračková Z; Trebatická J
    Oxid Med Cell Longev; 2015; 2015():898393. PubMed ID: 26078821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways.
    Anderson G; Maes M; Berk M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Apr; 42():101-14. PubMed ID: 22930036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychotropics in pregnancy: weighing the risks.
    Grover S; Avasthi A; Sharma Y
    Indian J Med Res; 2006 Apr; 123(4):497-512. PubMed ID: 16783040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders.
    Vawter MP; Tomita H; Meng F; Bolstad B; Li J; Evans S; Choudary P; Atz M; Shao L; Neal C; Walsh DM; Burmeister M; Speed T; Myers R; Jones EG; Watson SJ; Akil H; Bunney WE
    Mol Psychiatry; 2006 Jul; 11(7):615, 663-79. PubMed ID: 16636682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Indications for lithium salts in psychiatric therapeutics].
    Deniker P; Ginestet D; Lôo H; Colonna L
    Nouv Presse Med; 1972 Dec; 1(44):2959-62. PubMed ID: 4660967
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.